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Background: Retrospective data show significant maternal mortality and complications with high risk cardiovascular disease and pregnancy. 
Severe pulmonary hypertension (PH), severe left sided obstruction, cyanotic heart disease and cardiomyopathy (CMP) carries a 10-50% risk of 
maternal death during the peripartum period. A prospective multi-specialty approach to high risk patients (pts) presenting during pregnancy has not 
been reported. Therefore, we sought to determine if successful maternal outcome is achievable in high risk cardiovascular pregnancies utilizing an 
aggressive protocol of interventions and multi-specialty collaboration. 
Methods: Since 1999 we have prospectively managed women with heart disease and pregnancy. All pts are discussed and a specific protocol is 
devised by a team representing adult congenital heart disease, maternal fetal medicine, and cardiac anesthesia. From this database, we identified 
a high risk subgroup with severe PH, severe left sided obstruction, cyanosis and CMP with LVEF < 40 %. We recorded interventions and maternal 
outcome. Data were compared to predicted risk reported by Siu et al. 
Results: From 1999 - 2008, 186 women had 227 pregnancies with complete data for 211 pregnancies. There were 31 (14.7 %) high risk pts; 
severe PH in 5 (2.4%), cyanosis in 2 (0.9%), severe LVOTO in 12 (5.6%), severe mitral stenosis in 6 (2.8%), CMP in 6 (2.8%). Balloon valvuloplasty 
was performed 4, aortic stent in 1, aortic valve replacement in 1, and IV prostacyclin (PC) therapy in 4 pts. Maternal cardiovascular complication 
rate was significantly less than expected, 47% vs. 75% predicted by Siu et al. p< 0.001. There was 0% maternal mortality. 
Conclusions: Our study represents the largest single center cohort of cardiovascular disease in pregnancy and the first to report a prospective 
multi-specialty approach with emphasis on high risk patients. With an aggressive patient specific protocol to high risk pts including catheter-based 
and surgical interventions, advanced heart failure treatment, and IV PC therapy, successful outcome is achievable with an expectation of 0% 
maternal mortality. This model should be considered when caring for this high risk population.
